Main indications and scope of use of Teritusumab/Telivac

Teritusumab (Teclistamab-cqyv) is a type of bispecific antibody that has rapidly emerged in the field of global hematological tumors in recent years. It consists of BCMA and CD3 dual targets. It can connect tumor cells and T cells at the same time, allowing the body's immune system to re-recognize and eliminate malignant plasma cells. This new type of immunotherapy plays an important role in relapsed or refractory multiple myeloma (MM), especially in patients who have received multiple types of treatments but still have disease progression, providing new treatment options.

According to the guidelines, the main indication of teritusumab is in adult patients with multiple myeloma, and the medical history before use requires that they have received at least four types of therapies, including proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies. In other words, it is mainly used in late-line stages where the disease is complex, treatment resistance is strong, and drug options are limited. Such patients often undergo multiple chemotherapy or targeted regimens, and teritolumab, as an immune redirection therapy, can provide new intervention methods when traditional regimens have limited effects.

The mechanism of action of Teritusumab is very unique. BCMA is a key antigen on the surface of multiple myeloma cells, while CD3 is found on the surface of T cells. One end of the bispecific antibody binds to myeloma cells and the other end binds to T cells, thereby "drawing" the T cells to the tumor cells and inducing them to release cytotoxic factors to directly destroy malignant plasma cells. This mechanism, which does not require genetic modification and does not rely on cell reinfusion, makes it different from more complex immunotherapies such as CAR-T and is more accessible.

In terms of scope of medication, teritusumab is currently mainly used in adult patients, but multiple studies are ongoing overseas to evaluate whether it can be expanded to early treatment lines or combination regimens. For example, some studies have observed its combined use with proteasome inhibitors, immunomodulators and other drugs to try to build stronger immune synergy and leave more room for future treatment strategies.

Reference materials:https://www.tecvayli.com/